ArticleCancer immunology research2019
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01876511 (Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.Nature medicine · 2023Trial
- Clinicopathological and molecular profiling of sporadic synchronous multiple primary colorectal cancers: focus on microsatellite instability status.Journal of gastrointestinal oncology · 2026Article
- Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver Metastases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study.NPJ precision oncology · 2025Article
- Cell Senescence-Related Genes as Biomarkers for Prognosis and Immunotherapeutic Response in Colon Cancer.Biochemical genetics · 2025Article
- PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer.Cell communication and signaling : CCS · 2025Article
- Systematic Analysis of an Immune-Related Gene Signature for Predicting Prognosis and Immune Characteristics in Primary Lower Grade Glioma.BioMed research international · 2025Article
- Differential response to immunotherapy in different lesions of MSI-H double primary colorectal cancer: a case report and literature review.AME case reports · 2025Article
- Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.Medicina (Kaunas, Lithuania) · 2024Review
- Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment.PeerJ · 2024Article
- A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.International journal of molecular sciences · 2022Article
- Molecular Typing and Clinical Characteristics of Synchronous Multiple Primary Colorectal Cancer.JAMA network open · 2022Article
- Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon Cancer.Biomedicines · 2022Article
- Article
- Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.Frontiers in immunology · 2022Article
- Predictive biomarkers of colon cancer immunotherapy: Present and future.Frontiers in immunology · 2022Review
- The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer.International journal of molecular sciences · 2021Review
- A lipid metabolism-related genes prognosis biomarker associated with the tumor immune microenvironment in colorectal carcinoma.BMC cancer · 2021Article
- Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes.Journal of hematology & oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability-high (MSI-H) cancer. Despite this success, a large majority of metastatic colorectal cancer patients are not MSI-H and do not benefit from checkpoint blockade treatment. Predictive biomarkers to develop personalized medicines and guide clinical trials are needed for these patients. We, therefore, asked whether immunohistologic stratification of metastatic colorectal cancer based on primary tumor PD-L1 expression associated with the presence or absence of extracellular mucin defines a subset of metastatic colorectal cancer patients who exhibit a preexisting antitumor immune response and who could potentially benefit from the checkpoint blockade. To address this, we studied 26 advanced metastatic colorectal cancer patients treated with pembrolizumab (NCT01876511). To stratify patients, incorporation of histopathologic characteristics (percentage of extracellular mucin) and PD-L1 expression at the invasive front were used to generate a composite score, the CPM (composite PD-L1 and mucin) score, which discriminated patients who exhibited clinical benefit (complete, partial, or stable disease) from those patients with progressive disease. When validated in larger cohorts, the CPM score in combination with MSI testing may guide immunotherapy interventions for colorectal cancer patient treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.